» Articles » PMID: 20801877

Aberrant Overexpression of the Rgl2 Ral Small GTPase-specific Guanine Nucleotide Exchange Factor Promotes Pancreatic Cancer Growth Through Ral-dependent and Ral-independent Mechanisms

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2010 Aug 31
PMID 20801877
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Our recent studies established essential and distinct roles for RalA and RalB small GTPase activation in K-Ras mutant pancreatic ductal adenocarcinoma (PDAC) cell line tumorigencity, invasion, and metastasis. However, the mechanism of Ral GTPase activation in PDAC has not been determined. There are four highly related mammalian RalGEFs (RalGDS, Rgl1, Rgl2, and Rgl3) that can serve as Ras effectors. Whether or not they share distinct or overlapping functions in K-Ras-mediated growth transformation has not been explored. We found that plasma membrane targeting to mimic persistent Ras activation enhanced the growth-transforming activities of RalGEFs. Unexpectedly, transforming activity did not correlate directly with total cell steady-state levels of Ral activation. Next, we observed elevated Rgl2 expression in PDAC tumor tissue and cell lines. Expression of dominant negative Ral, which blocks RalGEF function, as well as interfering RNA suppression of Rgl2, reduced PDAC cell line steady-state Ral activity, growth in soft agar, and Matrigel invasion. Surprisingly, the effect of Rgl2 on anchorage-independent growth could not be rescued by constitutively activated RalA, suggesting a novel Ral-independent function for Rgl2 in transformation. Finally, we determined that Rgl2 and RalB both localized to the leading edge, and this localization of RalB was dependent on endogenous Rgl2 expression. In summary, our observations support nonredundant roles for RalGEFs in Ras-mediated oncogenesis and a key role for Rgl2 in Ral activation and Ral-independent PDAC growth.

Citing Articles

Structural insights into the complex of oncogenic KRas4B and Rgl2, a RalA/B activator.

Tariq M, Ikeya T, Togashi N, Fairall L, Kamei S, Mayooramurugan S Life Sci Alliance. 2023; 7(1).

PMID: 37833074 PMC: 10576006. DOI: 10.26508/lsa.202302080.


The RAL Enigma: Distinct Roles of RALA and RALB in Cancer.

Richardson D, Spehar J, Han D, Chakravarthy P, Sizemore S Cells. 2022; 11(10).

PMID: 35626682 PMC: 9139244. DOI: 10.3390/cells11101645.


Low expression of RalGAPs associates with the poorer overall survival of head and neck squamous cell carcinoma.

Liu S, Shi C, Wang X, Ma X, Gao P Transl Cancer Res. 2022; 10(12):5085-5094.

PMID: 35116360 PMC: 8799020. DOI: 10.21037/tcr-21-1489.


Epigenetic Alterations in Pancreatic Cancer Metastasis.

Wang S, Xu J, Ji K, Hwang C Biomolecules. 2021; 11(8).

PMID: 34439749 PMC: 8394313. DOI: 10.3390/biom11081082.


Ral GTPase is essential for actin dynamics and Golgi apparatus distribution in mouse oocyte maturation.

Sun M, Hu L, Zhao C, Lu X, Ren Y, Wang J Cell Div. 2021; 16(1):3.

PMID: 34112192 PMC: 8194175. DOI: 10.1186/s13008-021-00071-y.


References
1.
Hamad N, Elconin J, Karnoub A, Bai W, Rich J, Abraham R . Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 2002; 16(16):2045-57. PMC: 186434. DOI: 10.1101/gad.993902. View

2.
Lim K, Baines A, Fiordalisi J, Shipitsin M, Feig L, Cox A . Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell. 2005; 7(6):533-45. DOI: 10.1016/j.ccr.2005.04.030. View

3.
Reid T, Terry K, Casey P, Beese L . Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol. 2004; 343(2):417-33. DOI: 10.1016/j.jmb.2004.08.056. View

4.
Lok W, Klein R, Saif M . Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs. 2009; 21(4):339-50. DOI: 10.1097/CAD.0b013e3283350dd1. View

5.
Weaver A . Cortactin in tumor invasiveness. Cancer Lett. 2008; 265(2):157-66. PMC: 2460566. DOI: 10.1016/j.canlet.2008.02.066. View